Coherent Identifier About this item: 20.500.12592/kdjqzs

A cost-effectiveness analysis of recombinant human activated protein C for severe sepsis in the intensive care unit : Economic evaluation of activated protein C




The horizon of the study was extended to a stage where only five percent of the cohort was alive after hospital discharge to capture the major clinical and economic outcomes related to the treatment under study 8. The same time horizon has been applied to both costs and outcomes. [...] Baseline characteristics of the patients are summarized in Appendix A. 3.2 Costs: To determine the health care costs for patients with severe sepsis treated with conventional care, we estimated the following direct costs for the patients in our cohort: the cost of care per week in the intensive care unit, the cost of care per week on the hospital ward, and the cost of subsequent health care for ho [...] However, because most of the patients in the study shared the same disease code, the average cost per intensive care unit day was nearly identical regardless of whether the cost estimates from the Peter Lougheed Hospital were included. [...] This data is used to derive the indirect costs by taking a product of the proportion of the patients returning to work, the proportion of patients in our cohort under sixty, and the average annual income of $33,384. [...] The expected cost of the conventional care is CAN $74,000 and the expected cost of the activated protein C treatment is CAN $90,000, resulting an incremental cost of CAN $15,000.


health economics human capital mathematics medicine uncertainty cost-effectiveness analysis health care sensitivity analysis critical care sepsis clinical trial septicemia protein c blood proteins cost-effectiveness health sciences confidence interval cam donaldson cost–utility analysis intensive care medicine cohort cost-effective intensive care unit quality adjusted life year critical care medicine severe sepsis monte carlo simulation recombinant blood proteins